Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone versus placebo for prevention of postoperative atrial fibrillation after coronary artery bypass grafting
IRCT20120215009014N281Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Atrial fibrillation (AFib) comparing Routine treatment plus spironolactone with Routine treatment plus placebo (2 arms). Primary endpoints: Risk of atrial fibrillation and Ejection fraction. Started May 2019; status: completed.
02
Drugs
spironolactone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20120215009014N281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N281.